Download Poster (939.16 KB)

Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Available materials

Poster
Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

Alexei A. Grom, Shoghik Akoghlanian, Melissa Elder, Renee Modica, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Poster
Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Comparison of Diagnostic Journey and Utilization of Clinical Care Resources in Uncontrolled vs. Controlled Gout in the United States

Jigar Shah, Menaka Bhor, James Hawthorne, Nathan Meyer, Emily Goddard, Molly Edwards, Alastair Hinds, John A. Albert

Available materials

Poster
Publication
  • ISPOR •
  • 18 May, 2026 •
  • •

Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures: Results of a Real-World Survey in the United States

Andrew Sulich, Menaka Bhor, James Hawthorne, Emily Goddard, Molly Edwards, Alastair Hinds, Ted Mikuls

Publication
  • NKF •
  • 7 May, 2026 •
  • •

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

Nissreen Elfadawy, Rehan Azeem, Pirooz Parsa, Ben Peace, Yasir A. Qazi

Available materials

Poster
Publication
  • NKF •
  • 7 May, 2026 •
  • •

Treatment Patterns and Clinical Outcomes in Patients with both Uncontrolled Gout and Chronic Kidney Disease

Samuel Piedad, Pirooz Parsa, Menaka Bhor, Molly Edwards, Emily Goddard, Saravanan Balamuthusamy

Available materials

Poster
Publication
  • PRYSM •
  • 19 March, 2026 •
  • •

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

Alexei A. Grom, Shoghik Akoghlanian, Melissa Elder, Renee Modica, Steve Mallett, Brian Jamieson, Fabrizio De Benedetti

Available materials

Poster
Sign up for alerts